Is Legend Biotech Corporation (NASDAQ:LEGN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Legend Biotech Corporation at current levels.
Carvykti is becoming the standard-of-care multiple myeloma weapon, and Legend owns half the economics on a drug heading toward $5B-plus.
Where LEGN is headed
By end of 2027, Carvykti (cilta-cel) is on track to be the largest CAR-T franchise in oncology history, eclipsing Gilead's Yescarta and Novartis's Kymriah combined. The CARTITUDE-4 readout pushed cilta-cel into earlier lines of multiple myeloma therapy, and the FDA label expansion to second-line in 2024 was the inflection point most investors are still underestimating. Run-rate sales crossed $1B per quarter in early 2026, and the Janssen partnership splits profits roughly 50/50 after Legend's territory carve-outs. Do the math: a $5B-$6B drug throwing off ~$2.5B in Legend's share by 2028, against today's $6.7B market cap, is a setup the market is treating like a mid-cap biotech rather than a top-five oncology franchise owner.
Read the full Compass Direction on LEGN
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $35.87).
See the full LEGN analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Legend Biotech Corporation (NASDAQ:LEGN) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Legend Biotech Corporation at current levels. Carvykti is becoming the standard-of-care multiple myeloma weapon, and Legend owns half the economics on a drug heading toward $5B-plus.
What is LEGN's Compass Score?
Legend Biotech Corporation scores 76/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for LEGN?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the LEGN page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.